- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Chanan-Khan on Ibruitinib Combined with BR in CLL/SLL
May 30th 2015, 2:38pm
Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses a recent study that examined ibrutinib combined with bendamustine and ritxuimab (BR) in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Novel JAK Inhibitor Alleviates Key Myelofibrosis Symptoms
May 30th 2015, 1:51pm
Patients with myelofibrosis achieved significantly better outcomes in spleen volume reduction and symptom control with the novel JAK2 inhibitor pacritinib compared with best available therapy.
Daratumumab Data Impresses in Myeloma, FDA Submission Expected
May 30th 2015, 10:26am
Daratumumab demonstrated a 65% one-year overall survival rate and a 29.2% objective response rate in patients with double refractory heavily pretreated multiple myeloma.
Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study
May 30th 2015, 9:57am
Adding ibrutinib to standard bendamustine and rituximab (BR) reduced the risk of disease progression by 80% compared with BR plus placebo in patients with pretreated CLL or SLL.
Phase III Data Show Nivolumab Improves Survival Across Lung Cancer Subtypes
May 29th 2015, 3:59pm
Nivolumab has now been shown to have an overall survival benefit versus docetaxel in both nonsquamous and squamous non–small cell lung cancer.
Dr. Seiwert on Pembrolizumab in Head and Neck Cancer
May 29th 2015, 3:24pm
Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.
Study Opens Door for Nivolumab in HCC
May 29th 2015, 2:40pm
Nivolumab generated antitumor responses in nearly 20% of patients with advanced HCC in a small study that suggests a promising role for the immunotherapy agent in a malignancy with dismal outcomes.
Pembrolizumab Demonstrates "Remarkable Efficacy" in Advanced HNSCC
May 29th 2015, 2:14pm
In a multisite study offering the largest experience to date of how immunotherapy can be deployed in patients with head and neck cancer, the anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with advanced disease.
Mismatch Repair a Potential Biomarker for PD-1 Inhibition
May 29th 2015, 2:01pm
Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.
Dr. Burris on the Impact of the ASCO Annual Meeting
May 28th 2015, 3:09pm
Howard Burris, III, MD, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.
ASCO Highlights Include Phase III Findings in Multiple Tumor Types
May 27th 2015, 9:46am
Findings from large, late-stage clinical trials in melanoma, non–small cell lung cancer, and several hematologic malignances are expected to rank among the most clinically significant research findings presented at the 2015 American Society of Clinical Oncology Annual Meeting.
Radium-223 Survival Benefit Unaffected by Prior Hormonal Therapy
May 20th 2015, 2:13pm
Prior treatment with abiraterone acetate or enzalutamide did not alter the survival benefit seen with radium-223 in men with advanced castration-resistant prostate cancer.
Dr. Shore on the TERRAIN Trial for Prostate Cancer
May 20th 2015, 12:58pm
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses the results of the TERRAIN trial.
Lower CV Event Rate With Degarelix Versus LHRH Agonist Irrespective of Baseline Risk
May 20th 2015, 12:37pm
Prostate cancer patients with different baseline cardiovascular risk had similar reductions in cardiovascular event rates when treated with the LHRH antagonist degarelix versus an LHRH agonist.
Dr. Cooperberg on Using Antagonists for Hormonal Therapy in Prostate Cancer
May 19th 2015, 10:21am
Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the efficacy of using an antagonist with hormone therapy in prostate cancer.
Pembrolizumab Active in Advanced Urothelial Cancer
May 19th 2015, 9:30am
A fourth of patients with advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor pembrolizumab.
Combined Imaging Approach Effectively Detects Aggressive Prostate Cancer
May 18th 2015, 2:05pm
The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.
Proteoglycan Assay Shows Potential as Adjunct to PSA Measurement
May 18th 2015, 12:16pm
A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.
Sexual Function Scores Are Better After Robotic Versus Open Surgery for Prostate Cancer
May 18th 2015, 10:29am
Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.
Dr. Moul on Impact of Obesity in Active Surveillance
May 18th 2015, 8:05am
Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.